Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database
Open Access
- 31 July 2026
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Abstract
No abstract availableKeywords
All Related Versions
This publication has 40 references indexed in Scilit:
- History of glucagon-like peptide-1 receptor agonistsPharmacological Research, 2025
- GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 DiabetesJAMA Network Open, 2025
- Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatmentBiochemistry and Biophysics Reports, 2025
- Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy RegulationThe American Journal of Medicine, 2025
- Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese MiceJACC: Basic To Translational Science, 2024
- Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?JAMA, 2024
- Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT TrialsJournal of Cardiac Failure, 2023
- Duration of Diabetes and Incident Heart FailureJACC: Heart Failure, 2021
- Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2016
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion InjuryJACC, 2009